Tumors may mediate this resistance by activating angiogenic signaling independent of VEGF-A, cancer–stromal cell interactions, tumor endothelial cell heterogeneity, and physiological processes like vessel co-option and vascular mimicry [9,12,13,14,15]. This evidence concerns the gene VEGFA and neoplasm.